Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Autor: Janes, Matthew R., Zhang, Jingchuan, Li, Lian-Sheng, Hansen, Rasmus, Peters, Ulf, Guo, Xin, Chen, Yuching, Babbar, Anjali, Firdaus, Sarah J., Darjania, Levan, Feng, Jun, Chen, Jeffrey H., Li, Shuangwei, Li, Shisheng, Long, Yun O., Thach, Carol, Liu, Yuan, Zarieh, Ata, Ely, Tess, Kucharski, Jeff M., Kessler, Linda V., Wu, Tao, Yu, Ke, Wang, Yi, Yao, Yvonne, Deng, Xiaohu, Zarrinkar, Patrick P., Brehmer, Dirk, Dhanak, Dashyant, Lorenzi, Matthew V., Hu-Lowe, Dana, Patricelli, Matthew P., Ren, Pingda, Liu, Yi

Publikováno v: In Cell 25 January 2018 172(3):578-589

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Selective Inhibition of Phosphoinositide 3-Kinase p110? Preserves Lymphocyte Function*

Autor: So, Lomon, Yea, Sung Su, Oak, Jean S., Lu, Mengrou, Manmadhan, Arun, Ke, Qiao Han, Janes, Matthew R., Kessler, Linda V., Kucharski, Jeff M., Li, Lian-Sheng, Martin, Michael B., Ren, Pingda, Jessen, Katti A., Liu, Yi, Rommel, Christian, Fruman, David A.

Publikováno v: So, Lomon; Yea, Sung Su; Oak, Jean S.; Lu, Mengrou; Manmadhan, Arun; Ke, Qiao Han; et al.(2012). Selective Inhibition of Phosphoinositide 3-Kinase p110? Preserves Lymphocyte Function*. The Journal of Biological Chemistry, 288(8), 5718-5731. UC Irvine: Institute for Clinical and Translational Science. Retrieved from: http://www.escholarship.org/uc/item/6cp6h44b

Background: The class IA PI3K isoform p110α is a promising drug target in cancer therapy yet its role in lymphocytes is not known.Results: Lymphocyte function was minimally affected by p110α inhibition both in vitro and in vivo.Conclusion: Selectiv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::83151bc58ea581b877003a46e4efe87c
http://www.escholarship.org/uc/item/6cp6h44b